Biofarm Past Earnings Performance

Past criteria checks 3/6

Biofarm has been growing earnings at an average annual rate of 13.1%, while the Pharmaceuticals industry saw earnings growing at 14% annually. Revenues have been growing at an average rate of 10.8% per year. Biofarm's return on equity is 17.9%, and it has net margins of 25.3%.

Key information

13.1%

Earnings growth rate

12.7%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate10.8%
Return on equity17.9%
Net Margin25.3%
Next Earnings Update28 Feb 2024

Recent past performance updates

Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?

Feb 18
Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?

Recent updates

Is Biofarm S.A.'s (BVB:BIO) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Mar 18
Is Biofarm S.A.'s (BVB:BIO) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?

Feb 18
Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?

Shareholders Of Biofarm (BVB:BIO) Must Be Happy With Their 140% Total Return

Jan 23
Shareholders Of Biofarm (BVB:BIO) Must Be Happy With Their 140% Total Return

A Look At The Intrinsic Value Of Biofarm S.A. (BVB:BIO)

Dec 25
A Look At The Intrinsic Value Of Biofarm S.A. (BVB:BIO)

Could The Biofarm S.A. (BVB:BIO) Ownership Structure Tell Us Something Useful?

Dec 03
Could The Biofarm S.A. (BVB:BIO) Ownership Structure Tell Us Something Useful?

Revenue & Expenses Breakdown
Beta

How Biofarm makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BVB:BIO Revenue, expenses and earnings (RON Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 23297751170
30 Jun 23301771160
31 Mar 23297761120
31 Dec 22277711060
30 Sep 22269711010
30 Jun 2226068980
31 Mar 2225365940
31 Dec 2123960900
30 Sep 2124164900
30 Jun 2123161860
31 Mar 2121558800
31 Dec 2021654820
30 Sep 2021456800
30 Jun 2020552810
31 Mar 2021153880
31 Dec 1919551750
30 Sep 1918942880
30 Jun 1919544640
31 Mar 1918943650
31 Dec 1818438640
30 Sep 1817943610
30 Jun 1817138640
31 Mar 1817639590
31 Dec 1717036580
30 Sep 1716735530
30 Jun 1716535550
31 Mar 1715532520
31 Dec 1615229520
30 Sep 1614929450
30 Jun 1614827580
31 Mar 1613820440
31 Dec 1514927440
30 Sep 1514727480
30 Jun 1513827340
31 Mar 1513830470
31 Dec 1412927460
30 Sep 1412228430
30 Jun 1412027540
31 Mar 1412127430
31 Dec 1311826430
30 Sep 1311322520
30 Jun 1311022400
31 Mar 1311123430

Quality Earnings: BIO has high quality earnings.

Growing Profit Margin: BIO's current net profit margins (25.3%) are lower than last year (26.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BIO's earnings have grown by 13.1% per year over the past 5 years.

Accelerating Growth: BIO's earnings growth over the past year (5.5%) is below its 5-year average (13.1% per year).

Earnings vs Industry: BIO earnings growth over the past year (5.5%) exceeded the Pharmaceuticals industry 3.9%.


Return on Equity

High ROE: BIO's Return on Equity (17.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.